title: Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
abstract: The clinical value of plasma Epstein-Barr virus (EBV) DNA has not been evaluated in patients with early-stage extranodal nasal-type NK/T-cell lymphoma (NKTCL) receiving primary radiotherapy. Fifty-eight patients with stage I disease and 11 with stage II disease were recruited. High pretreatment EBV-DNA concentrations were associated with B-symptoms, elevated lactate dehydrogenase levels, and a high International Prognostic Index score. EBV-DNA levels significantly decreased after treatment. The 3-year overall survival (OS) rate was 82.6% for all patients. Stage I or II patients with a pretreatment EBV-DNA level of ≤ 500 copies/mL had 3-year OS and progression-free survival (PFS) rates of 97.1% and 79.0%, respectively, compared with 66.3% (P = .002) and 52.2% (P = .045) in patients with EBV-DNA levels of > 500 copies/mL. The 3-year OS and PFS rates for patients with undetectable EBV-DNA after treatment was significantly higher than patients with detectable EBV-DNA (OS, 92.0% vs 69.8%, P = .031; PFS, 77.5% vs 50.7%, P = .028). Similar results were observed in stage I patients. EBV-DNA levels correlate with tumor load and a poorer prognosis in early-stage NKTCL. The circulating EBV-DNA level could serve both as a valuable biomarker of tumor load for the accurate classification of early-stage NKTCL and as a prognostic factor.
authors: Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
authors: Zhao-Yang
authors: ZY
authors: Wang
authors: Qing-Feng
authors: QF
authors: Liu
authors: Hua
authors: H
authors: Wang
authors: Jing
authors: J
authors: Jin
authors: Wei-Hu
authors: WH
authors: Wang
authors: Shu-Lian
authors: SL
authors: Wang
authors: Yong-Wen
authors: YW
authors: Song
authors: Yue-Ping
authors: YP
authors: Liu
authors: Hui
authors: H
authors: Fang
authors: Hua
authors: H
authors: Ren
authors: Run-Ye
authors: RY
authors: Wu
authors: Bo
authors: B
authors: Chen
authors: Xi-Mei
authors: XM
authors: Zhang
authors: Ning-Ning
authors: NN
authors: Lu
authors: Li-Qiang
authors: LQ
authors: Zhou
authors: Ye-Xiong
authors: YX
authors: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D004279:DNA, Viral / Q000097:blood*; D018572:Disease-Free Survival; D042241:Early Diagnosis; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000175:diagnosis / Q000532:radiotherapy / Q000821:virology; D005260:Female; D004854:Herpesvirus 4, Human / Q000502:physiology; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D054391:Lymphoma, Extranodal NK-T-Cell / Q000150:complications* / Q000175:diagnosis / Q000532:radiotherapy / Q000821:virology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D011839:Radiation, Ionizing; D019562:Viral Load
chemical_list: D014408:Biomarkers, Tumor; D004279:DNA, Viral; D007770:L-Lactate Dehydrogenase